Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Pretreated Advanced Melanoma
2024-514087-11-02Phase 2Authorised
- Sponsor
- UZ Brussel
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regorafenib in melanoma (3 cohorts), sponsored by UZ Brussel. Primary endpoint: Objective response rate (ORR). Planned start Sep 2024; status: authorised.
02
Drugs
regorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-514087-11-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514087-11-02.